No evidence-based treatment options are available for patients with advanced colorectal cancer (CRC)
Background: No evidence-based treatment options are available for patients with advanced colorectal cancer (CRC) progressing after standard therapies. MGMT is involved in repair of DNA damage and MGMT promoter methylation may predict benefit from alkylating agents such as temozolomide. The aim of our study was to evaluate the activity of temozolomide in terms of response rate in patients with metastatic CRC and MGMT methylation, after failure of approved treatments. Results: Thirty-two patients were enrolled from August 2012 to July 2013. Treatment was well tolerated with one grade 4 thrombocytopenia and no other grade ≥3 toxicities. No complete response occurred. The objective response rate was 12%, reaching the pre-specified level for promising activity. Median progression-free survival and overall survival were 1.8 and 8.4 months, respectively. Patients with KRAS, BRAF and NRAS wild-type CRC showed significantly higher response when compared with those with any RAS or BRAF mutation (44% versus 0%; P = 0.004). TP53 status had no influence on the primary end point.
Patients and methods:

Conclusions:
Temozolomide is tolerable and active in heavily pre-treated patients with advanced CRC and MGMT promoter methylation. Further studies in biomolecularly enriched populations or in a randomized setting are necessary to demonstrate the efficacy of temozolomide after failure of standard treatments. Key words: colorectal cancer, temozolomide, MGMT, clinical trial introduction Treatment strategies for colorectal cancer (CRC) have changed in the past 10 years and resulted in significant improvement of survival. When deemed not suitable for surgical resection, patients with metastatic CRC are still not curable with available treatments. Several drugs including cytotoxics (fluoropyrimidines, oxaliplatin, irinotecan), the antiangiogenic agents bevacizumab and aflibercept and the anti-EGFR monoclonal antibodies cetuximab and panitumumab-either given in combination or as monotherapy in KRAS wild-type CRC-demonstrated to improve outcomes [1] . Recently, a randomized, double-blind, placebo-controlled, phase III trial met its primary end point of significant improvement of overall survival (OS) in patients receiving regorafenib-a multi-targeted tyrosine kinase inhibitorwhen compared with placebo after failure of standard treatments [2] . As a matter of fact, there are no effective drugs currently available beyond the approved treatments.
The DNA repair gene O 6 -methylguanine-DNA methyltransferase (MGMT) is responsible of the elimination of alkyl groups from the O 6 -position of guanine. If inactive, it may be involved in early steps of colorectal tumorigenesis through an increase of the mutational rate-particularly, G-to-A point mutations of KRAS gene [3, 4] . In several tumour types, the protein encoded by the MGMT repairs DNA damages induced by alkylating agents [5, 6] . Epigenetic silencing of MGMT during colorectal tumorigenesis is associated with hypermethylation of the CpG island in its promoter [7] . This transcriptional gene silencing is
